Protein Kinase Inhibitors: all 15,278 studies that test it

Page 97 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04094142Phase 2
• Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy SubjectsCompletedNCT04092725Phase 1
• Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male VolunteersCompletedNCT04092712Phase 1
• A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy ParticipantsCompletedNCT04092595Phase 1
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy ParticipantsCompletedNCT04090047Phase 1
• Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy RegimensStatus unknownNCT04089657Phase 2
• A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Active, not recruitingNCT04088396Phase 3
• Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerStatus unknownNCT04088110Phase 2
• Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1
• A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerCompletedNCT04087174Phase 1
• An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.CompletedNCT04086719Phase 1
• Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompletedNCT04085315Phase 1
• Study of Crizotinib for ROS1 and MET Activated Lung CancerCompletedNCT04084717Phase 2
• LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyCompletedNCT04081259Phase 1
• Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC PatientsCompletedNCT04080843Phase 2
• Study of Anlotinib After Lenvatinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04080154Phase 2
• Safety and Efficacy of Low-dose Sirolimus to Kaposiform HemangioendotheliomaCompletedNCT04077515Phase 4
• A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04077463Phase 1
• Brigatinib in ALK-positive NSCLC Identified Via Blood-based AssaysActive, not recruitingNCT04074993Phase 2
• Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6TerminatedNCT04074785Early Phase 1
• Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingNCT04074096Phase 2
• A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid TumorsStatus unknownNCT04073680Phase 1/2
• A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)TerminatedNCT04073615Phase 1
• Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung CancerStatus unknownNCT04073550Phase 3
• Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung CancerStatus unknownNCT04073537Phase 3
• A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced CancerCompletedNCT04071262Phase 1
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingNCT04071236Phase 1/2
• Study of Alofanib in Patients With Metastatic Gastric CancerStatus unknownNCT04071184Phase 1
• Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host DiseaseTerminatedNCT04070781Phase 1
• Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseActive, not recruitingNCT04070443Phase 2
• Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor ThrombusStatus unknownNCT04069949Phase 1/2
• Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian CancerStatus unknownNCT04068974Phase 2
• Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingNCT04068194Phase 1/2
• Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal CancerStatus unknownNCT04067986Phase 1/2
• Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerTerminatedNCT04066790Phase 2
• Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.TerminatedNCT04066595Phase 2
• TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT04066543Phase 2
• A Study to Determine the Pharmacokinetic Profile of BMS-986165 TabletsCompletedNCT04065932Phase 1
• Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionWithdrawnNCT04064190Phase 2
• Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.Status unknownNCT04063683Phase 2
• Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion MutationStatus unknownNCT04063462Phase 2
• Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvementStatus unknownNCT04062695Phase 2
• Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerActive, not recruitingNCT04061980Phase 2
• First Line Therapy for High Risk Acute GVHDCompletedNCT04061876Phase 2
• A Study of HS-10342 in Patients With Advanced Solid TumorCompletedNCT04060511Phase 1
• Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPCCompletedNCT04060394Phase 1/2
• Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene SulfonateStatus unknownNCT04059874Phase 1
• TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaCompletedNCT04059224Phase 2
• A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation TherapyStatus unknownNCT04058704Phase 3
• A Phase I Trial of Simmitinib in Advanced Solid TumorsStatus unknownNCT04058587Phase 1
• Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibStatus unknownNCT04056572Phase 2
• A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy ParticipantsCompletedNCT04055506Phase 1
• Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCActive, not recruitingNCT04055493Phase 3
• The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT04053972Phase 3
• To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET DysregulationCompletedNCT04052971Phase 1
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingNCT04052555Phase 1
• Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Phase 2
• Regorafenib in Bevacizumab Refractory Recurrent GlioblastomaCompletedNCT04051606Phase 2
• A Phase I Study of YY-20394 in Patients With Advanced Solid TumorsStatus unknownNCT04049929Phase 1
• Abemaciclib and Letrozole in Treating Patients With Endometrial CancerCompletedNCT04049227Early Phase 1
• Study of Sirolimus in Idiopathic Retroperitoneal FibrosisCompletedNCT04047576Phase 2/3
• Camrelizumab Combined With Apatinib for Recurrent Resistant GTNCompletedNCT04047017Phase 2
• Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1
• HAIC Plus Lenvatinib and Toripalimab for Advanced HCCCompletedNCT04044313Phase 2
• Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT04044170Phase 2
• Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04043676Phase 2
• Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular CarcinomaStatus unknownNCT04042805Phase 2
• Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic ChordomaStatus unknownNCT04042597Phase 2
• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorSuspendedNCT04042116Phase 1/2
• Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerTerminatedNCT04042051Phase 1
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingNCT04041050Phase 1
• Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionWithdrawnNCT04040725Phase 2
• A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerActive, not recruitingNCT04036682Phase 1/2
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisCompletedNCT04036435Phase 3
• Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver TransplantStatus unknownNCT04035876Phase 1/2
• A Study of LY3214996 in Healthy ParticipantsCompletedNCT04033341Phase 1
• Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )Status unknownNCT04033172Phase 2
• Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial CancerTerminatedNCT04030429Phase 2
• Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal CancerStatus unknownNCT04030260Phase 2
• Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLCStatus unknownNCT04028778Phase 3
• Phase 2 Study of Dacomitinib in NSCLCActive, not recruitingNCT04027647Phase 2
• A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyActive, not recruitingNCT04027309Phase 3
• BAriCitinib Healing Effect in earLy pOlymyalgia RheumaticaCompletedNCT04027101Phase 2
• Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
• RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic SyndromeTerminatedNCT04021368Phase 1
• CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
• Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive SteroidsCompletedNCT04018274Phase 1
• BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
• CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSCompletedNCT04017546Phase 1
• Dual PD-1 and JAK2 Inhibition in Hematological MalignanciesWithdrawnNCT04016116Phase 2
• A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML PatientsStatus unknownNCT04015024Phase 2
• A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ MalignanciesCompletedNCT04014257Phase 1
• A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesActive, not recruitingNCT04014205Phase 1/2
• Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue SarcomaStatus unknownNCT04012827Phase 2
• Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic LeukemiaCompletedNCT04010968Phase 2
• Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCCompletedNCT04010357Phase 2
• Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant TumorsStatus unknownNCT04010071Phase 2
• Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT04009317Phase 3

← Protein Kinase Inhibitors overview